Cancer metabolism: looking forward
I Martínez-Reyes, NS Chandel - Nature Reviews Cancer, 2021 - nature.com
Tumour initiation and progression requires the metabolic reprogramming of cancer cells.
Cancer cells autonomously alter their flux through various metabolic pathways in order to …
Cancer cells autonomously alter their flux through various metabolic pathways in order to …
RAS-targeted therapies: is the undruggable drugged?
AR Moore, SC Rosenberg, F McCormick… - Nature reviews Drug …, 2020 - nature.com
Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like
(APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven …
(APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven …
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …
structures or functions that are difficult to interfere with using conventional drug design …
The metabolic landscape of RAS-driven cancers from biology to therapy
S Mukhopadhyay, MG Vander Heiden, F McCormick - Nature cancer, 2021 - nature.com
Our understanding of how the RAS protein family, and in particular mutant KRAS, promotes
metabolic dysregulation in cancer cells has advanced substantially over the last decade. In …
metabolic dysregulation in cancer cells has advanced substantially over the last decade. In …
Emerging strategies to target RAS signaling in human cancer therapy
K Chen, Y Zhang, L Qian, P Wang - Journal of hematology & oncology, 2021 - Springer
Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …
Targeting the PI3K pathway in cancer: are we making headway?
F Janku, TA Yap, F Meric-Bernstam - Nature reviews Clinical oncology, 2018 - nature.com
Abstract The PI3K–AKT–mTOR pathway is one of the most frequently dysregulated
pathways in cancer and, consequently, more than 40 compounds that target key …
pathways in cancer and, consequently, more than 40 compounds that target key …
PI3K inhibitors in cancer: clinical implications and adverse effects
The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway
which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian …
which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian …
Mitochondria as playmakers of apoptosis, autophagy and senescence
Mitochondria are the key energy-producing organelles and cellular source of reactive
species. They are responsible for managing cell life and death by a balanced homeostasis …
species. They are responsible for managing cell life and death by a balanced homeostasis …
The relation between PI3K/AKT signalling pathway and cancer
Abstract Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular
signalling in response to the extracellular stimulators. Hyperactivation of PI3K signalling …
signalling in response to the extracellular stimulators. Hyperactivation of PI3K signalling …